Circulating Mitochondrial Nucleic Acids Have Prognostic Value for Survival in Patients with Advanced Prostate Cancer
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose: Advanced prostate cancer represents a heterogeneous disease entity with differences in clinical behavior, response to therapy, and survival. We assessed whether we could distinguish poor from good prognosis patients at presentation in our clinic by means of quantifying circulating cell-free mitochondrial and genomic nucleic acids in plasma. Experimental Design: We collected plasma from 75 prostate cancer patients and from 14 subjects with benign disease. Nucleic acids were isolated, and mitochondrial DNA (mtDNA; 16S rRNA), mitochondrial RNA (mtRNA; cytochrome c oxidase subunit 1), and genomic DNA (U1A DNA) transcripts were quantified by real-time amplification. An association between cell-free nucleic acids and metastasis, prostate-specific antigen doubling time, and hemoglobin levels was determined. Multivariate Cox proportional hazard and survival estimation studies were done. Results: We show that elevated mtDNA and mtRNA levels are present in plasma of prostate cancer patients with a poor 2-year survival (P = 0.02 and 0.003, respectively). Cancer patients with high plasma mitochondrial nucleic acids, using a calculated optimal cutoff point, show a decreased survival compared with patients with low levels (35% versus 73% cumulative survival for mtDNA and 21% versus 73% for mtRNA). Multivariate analysis indicates that mtRNA is an independent predictor of 2-year survival. Conclusions: Quantification of plasma mitochondrial nucleic acids may be used to recognize patients with a poor prognosis. In advanced prostate cancer patients, mtRNA seemed the strongest predictor of overall survival and an independent prognostic factor for cancer-related death. Amplification of mitochondrial nucleic acids shows increased sensitivity and specificity over genomic DNA as diagnostic and prognostic marker in prostate cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giacona, M. B., Ruben, G. C., Iczkowski, K. A., Roos, T. B., Porter, D. M., & Sorenson, G. D. (1998) · Pancreas · doi:10.1097/00006676-199807000-00012 · Cited by 387
Isolation and characterization of DNA from the plasma of cancer patients
Stroun, M., Anker, P., Lyautey, J., Lederrey, C., & Maurice, P. A. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90266-5 · Cited by 373
Cited by
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
The Roles of Mitochondrial Damage-Associated Molecular Patterns in Diseases
Nakahira, K., Hisata, S., & Choi, A. M. K. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6407 · Cited by 360
Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors
Zachariah, R. R., Schmid, S., Buerki, N., Radpour, R., Holzgreve, W., & Zhong, X. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181867bc0 · Cited by 142
“Although Mehra et al (2007) showed an elevated plasma mitochondrial DNA level in patients with advanced prostate cancer,12 Elliger et al (2008) could not find any significance between benign and malignant prostate lesions in terms of serum circulating cell-free mitochondrial DNA.13 However, levels…”
Backgroundccf-mtDNA as a Potential Link Between the Brain and Immune System in Neuro-Immunological Disorders
Gambardella, S., Limanaqi, F., Ferese, R., Biagioni, F., Campopiano, R., Centonze, D., & Fornai, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01064 · Cited by 141
“mitomiRs disrupt the respiratory chain complexes (2) and increase ROS production (3) thus producing mitochondrial damage,”
BackgroundEllinger, J., Albers, P., Müller, S. C., Von Ruecker, A., & Bastian, P. J. (2009) · BJU International · doi:10.1111/j.1464-410x.2008.08289.x · Cited by 112
Metadata
- Authors
- Mehra, N., Penning, M., Maas, J., van Daal, N., Giles, R. H., & Voest, E. E.
- Venue
- Clinical Cancer Research
- Published
- 2007-01-15
- Volume
- 13
- Issue
- 2
- Pages
- 421-426
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2159529973
- Cited by
- 115
- References
- 2
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating Mitochondrial Nucleic Acids Have Prognostic Value for Survival in Patients with Advanced Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-1087
- The paper
- Mehra, N., Penning, M., Maas, J., van Daal, N., Giles, R. H., & Voest, E. E. (2007). Circulating Mitochondrial Nucleic Acids Have Prognostic Value for Survival in Patients with Advanced Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-1087
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.